Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Kessel

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Nature Biotechnology|March 9, 2012
Know before you goMark Kessel
Nature Biotechnology|February 11, 2009
A lifeline for the biotech sectorMark Kessel
Nature Biotechnology|June 10, 2014
Diagnostics as the first line of defense in global health securityMark Kessel
Nature Biotechnology|September 9, 2015
Why microbial diagnostics need more than moneyMark Kessel
Nature Biotechnology|December 10, 2013
Do you really want to be a biotech board member?Mark Kessel
Science Translational Medicine|March 7, 2014
Neglected diseases, delinquent diagnosticsMark Kessel
Nature Biotechnology|October 10, 2014
Restoring the pharmaceutical industry's reputationMark Kessel
Nature Biotechnology|January 12, 2011
The problems with today's pharmaceutical business--an outsider's viewMark Kessel
Nature Biotechnology|December 14, 2011
Sarbanes-Oxley overburdens biotech companiesMark Kessel
Nature Biotechnology|May 10, 2014
Reducing the burden of disclosure for public biotech companiesRobert Evans, Mark Kessel
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Nature Biotechnology|March 9, 2012
Know before you goMark Kessel
Nature Biotechnology|February 11, 2009
A lifeline for the biotech sectorMark Kessel
Nature Biotechnology|June 10, 2014
Diagnostics as the first line of defense in global health securityMark Kessel
Nature Biotechnology|September 9, 2015
Why microbial diagnostics need more than moneyMark Kessel
Nature Biotechnology|December 10, 2013
Do you really want to be a biotech board member?Mark Kessel
Science Translational Medicine|March 7, 2014
Neglected diseases, delinquent diagnosticsMark Kessel
Nature Biotechnology|October 10, 2014
Restoring the pharmaceutical industry's reputationMark Kessel
Nature Biotechnology|January 12, 2011
The problems with today's pharmaceutical business--an outsider's viewMark Kessel
Nature Biotechnology|December 14, 2011
Sarbanes-Oxley overburdens biotech companiesMark Kessel
Nature Biotechnology|May 10, 2014
Reducing the burden of disclosure for public biotech companiesRobert Evans, Mark Kessel
Pageof 3